Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) announced that CEO Dr. Amit Kumar will present at the 2025 CAGLA NeauxCancer Conference on March 28th, 2025, at 10:00 AM CDT in New Orleans. The presentation, taking place at The Roosevelt Hotel, will showcase Anixa's innovative cancer treatment programs.
Dr. Kumar will provide updates on the company's cutting-edge CAR-T therapy for solid tumors and novel cancer vaccine initiatives. The presentation will highlight Anixa's progress in clinical development and their approach to advancing next-generation immunotherapies in cancer care.
The CAGLA NeauxCancer Conference, scheduled for March 27-29, 2025, brings together oncology researchers, industry executives, investors, and medical professionals to discuss breakthrough developments in cancer treatment.
Positive
- None.
Negative
- None.
News Market Reaction – ANIX
On the day this news was published, ANIX gained 2.36%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Dr. Kumar's presentation will provide an overview of Anixa's pioneering programs in cancer treatment, including updates on its cutting-edge CAR-T therapy for solid tumors and its novel cancer vaccine initiatives. He will discuss the Company's latest progress in clinical development and how Anixa is advancing next-generation immunotherapies to transform cancer care.
Details of the presentation are as follows:
Event: 2025 CAGLA NeauxCancer Conference
Date: March 28, 2025
Time: 10:00 AM CDT
Location: The Roosevelt New Orleans
Webcast: CAGLA 2025 Livestreams
The CAGLA NeauxCancer Conference is a premier gathering of leading oncology researchers, industry executives, investors and medical professionals focused on groundbreaking developments in cancer treatment and care.
For more information about the conference, visit https://cag-la.org/neauxcancer-2025/.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-ceo-to-present-at-the-2025-cagla-neauxcancer-conference-on-march-28th-302401546.html
SOURCE Anixa Biosciences, Inc.
FAQ
When and where will Anixa Biosciences (ANIX) present at the 2025 CAGLA NeauxCancer Conference?
What cancer treatment programs will Anixa Biosciences (ANIX) discuss at the CAGLA conference?
Is the 2025 CAGLA NeauxCancer Conference presentation by Anixa (ANIX) available online?
What is the significance of Anixa's (ANIX) presentation at the 2025 CAGLA Conference?
How long does the 2025 CAGLA NeauxCancer Conference run where Anixa (ANIX) is presenting?
